BR112021010134A2 - Métodos de tratamento de transtornos mieloproliferativos - Google Patents

Métodos de tratamento de transtornos mieloproliferativos Download PDF

Info

Publication number
BR112021010134A2
BR112021010134A2 BR112021010134-9A BR112021010134A BR112021010134A2 BR 112021010134 A2 BR112021010134 A2 BR 112021010134A2 BR 112021010134 A BR112021010134 A BR 112021010134A BR 112021010134 A2 BR112021010134 A2 BR 112021010134A2
Authority
BR
Brazil
Prior art keywords
subject
individual
ruxolitinib
treatment
day
Prior art date
Application number
BR112021010134-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Adrian Senderowicz
Michael Cooper
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of BR112021010134A2 publication Critical patent/BR112021010134A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112021010134-9A 2018-11-27 2018-11-27 Métodos de tratamento de transtornos mieloproliferativos BR112021010134A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
BR112021010134A2 true BR112021010134A2 (pt) 2021-08-24

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010134-9A BR112021010134A2 (pt) 2018-11-27 2018-11-27 Métodos de tratamento de transtornos mieloproliferativos

Country Status (8)

Country Link
JP (2) JP7453230B2 (https=)
KR (2) KR102738936B1 (https=)
AU (1) AU2018451360B2 (https=)
BR (1) BR112021010134A2 (https=)
CA (1) CA3120973A1 (https=)
EA (1) EA202191489A1 (https=)
SG (1) SG11202105279SA (https=)
WO (1) WO2020112086A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006205A (es) 2018-11-27 2021-10-13 Constellation Pharmaceuticals Inc Metodos de tratamiento de trastornos mieloproliferativos.
EA202191489A1 (ru) * 2018-11-27 2021-09-10 Констеллейшен Фармасьютикалс, Инк. Способы лечения миелопролиферативных расстройств
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
IL300337A (en) * 2020-08-04 2023-04-01 Constellation Pharmaceuticals Inc 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[5,4-E]azepin-4-yl)acetamide for the treatment of thrombocythemia
WO2025155120A1 (ko) 2024-01-18 2025-07-24 주식회사 엘지에너지솔루션 전극조립체, 이차 전지 및 배터리 유닛

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
EA202191489A1 (ru) * 2018-11-27 2021-09-10 Констеллейшен Фармасьютикалс, Инк. Способы лечения миелопролиферативных расстройств

Also Published As

Publication number Publication date
WO2020112086A1 (en) 2020-06-04
KR20250004357A (ko) 2025-01-07
AU2018451360A1 (en) 2021-06-10
JP2024063214A (ja) 2024-05-10
CA3120973A1 (en) 2020-06-04
SG11202105279SA (en) 2021-06-29
KR102738936B1 (ko) 2024-12-06
EA202191489A1 (ru) 2021-09-10
AU2018451360B2 (en) 2022-05-26
JP2022519425A (ja) 2022-03-24
KR20210095904A (ko) 2021-08-03
JP7453230B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
BR112021010134A2 (pt) Métodos de tratamento de transtornos mieloproliferativos
US12070464B2 (en) Methods of treating myeloproliferative disorders
O'Sullivan et al. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
MX2012014416A (es) Tratamiento de cancer de sangre.
Bournia et al. Recent advances in the treatment of systemic sclerosis
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
US20240269146A1 (en) Use of pelabresib for treating anemias
KR20230110751A (ko) 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제
EA047870B1 (ru) Способы лечения миелопролиферативных расстройств
WO2021091532A1 (en) Methods of treating myeloproliferative disorders
WO2020256739A1 (en) Methods of treating myeloproliferative disorders
AU2020422620B2 (en) Use of ketamine in the treatment of cachexia
WO2025002346A1 (zh) 含pd-l1小分子抑制剂的药物组合及其应用
CN112294817B (zh) 多韦替尼用于治疗高尿酸相关疾病的用途
EA050232B1 (ru) Способы лечения анемий
WO2021014812A1 (ja) 線維芽細胞性又は筋線維芽細胞性腫瘍・疾患の治療

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]